Moreover, antibodies targeting CCR8 such as GS-1811, S-531011, and 2MW4691 allow for highly specific depletion of tumor-resident Tregs via antibody-dependent cellular cytotoxicity (ADCC), promoting the expansion of CD8+ T cells and improving tumor control (63–67). Here, CD8A is linked to neoplasm.